Codexis Inc
NASDAQ:CDXS
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
1.94
4.65
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one CDXS stock under the Base Case scenario is 2.92 USD. Compared to the current market price of 4.61 USD, Codexis Inc is Overvalued by 37%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Codexis Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for CDXS cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Codexis Inc
Balance Sheet Decomposition
Codexis Inc
Current Assets | 112.9m |
Cash & Short-Term Investments | 90.3m |
Receivables | 16.5m |
Other Current Assets | 6.1m |
Non-Current Assets | 35.3m |
Long-Term Investments | 5.8m |
PP&E | 24m |
Intangibles | 2.5m |
Other Non-Current Assets | 3m |
Current Liabilities | 35.1m |
Accounts Payable | 4.2m |
Accrued Liabilities | 20.9m |
Other Current Liabilities | 10m |
Non-Current Liabilities | 39.7m |
Long-Term Debt | 28.6m |
Other Non-Current Liabilities | 11m |
Earnings Waterfall
Codexis Inc
Revenue
|
64.4m
USD
|
Cost of Revenue
|
-15.5m
USD
|
Gross Profit
|
49m
USD
|
Operating Expenses
|
-99.7m
USD
|
Operating Income
|
-50.7m
USD
|
Other Expenses
|
-11.4m
USD
|
Net Income
|
-62.1m
USD
|
Free Cash Flow Analysis
Codexis Inc
USD | |
Free Cash Flow | USD |
CDXS Profitability Score
Profitability Due Diligence
Codexis Inc's profitability score is 17/100. The higher the profitability score, the more profitable the company is.
Score
Codexis Inc's profitability score is 17/100. The higher the profitability score, the more profitable the company is.
CDXS Solvency Score
Solvency Due Diligence
Codexis Inc's solvency score is 46/100. The higher the solvency score, the more solvent the company is.
Score
Codexis Inc's solvency score is 46/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CDXS Price Targets Summary
Codexis Inc
According to Wall Street analysts, the average 1-year price target for CDXS is 6.99 USD with a low forecast of 3.03 USD and a high forecast of 11.55 USD.
Dividends
Current shareholder yield for CDXS is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
CDXS Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Codexis, Inc. is an enzyme engineering company, which engages in the development and sale of therapeutics. The company is headquartered in Redwood City, California and currently employs 261 full-time employees. The company went IPO on 2010-04-22. The firm is engaged in discovering, developing and sells enzymes and other proteins. The company operates through two segments: Performance Enzymes and Novel Biotherapeutics. The Company’s CodeEvolver technology platform accelerates biologic discovery through the transformation of a starting enzyme into a biocatalyst or therapeutic candidate. The firm has commercialized its CodeEvolver protein engineering technology platform and products in the pharmaceutical’s markets. Its products include biocatalysts, chemical intermediates and Codex biocatalyst panels and kits. The company also commercialized three additional enzymes, such as Codex HiFi DNA Polymerase for use in next generation sequencing, Codex HiTemp Reverse Transcriptase for use in molecular diagnostic applications, and Codex HiCap RNA Polymerase for use in RNA synthesis applications. The firm is developing its lead program, CDX-6114 for the treatment of hyperphenylalaninemia (HPA).
Contact
IPO
Employees
Officers
The intrinsic value of one CDXS stock under the Base Case scenario is 2.92 USD.
Compared to the current market price of 4.61 USD, Codexis Inc is Overvalued by 37%.